Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy
Omalizumab, a recombinant humanized monoclonal antibody, is the first approved anti-immunoglobulin E (IgE) agent for the treatment of subjects with moderate to severe persistent allergic asthma that are inadequately controlled by the standard of care. The objective of this study was to quantitativel...
Saved in:
Published in | The AAPS journal Vol. 15; no. 2; pp. 559 - 570 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston
Springer US
01.04.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!